RecruitingNCT06060041
IC-8 Apthera IOL New Enrollment Post Approval Study
Sponsor
Bausch & Lomb Incorporated
Enrollment
435 participants
Start Date
Sep 8, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.
Eligibility
Min Age: 22 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with cataract, posterior capsule opacification, and other related conditions. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 22 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06060041
Related Trials
JASPER™ Robotic Surgical System (Formerly Known as the ORYOM™ Robotic Surgical System) in Cataract Surgery
NCT074684091 location
Post-refractive IOL Outcomes With Clareon TruPlus
NCT076102261 location
Toric Performance And Constant Evaluation
NCT074712956 locations
Randomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery
NCT077155911 location
A Prospective, Randomized, Subject- and Examiner-Masked, Multicenter Study Comparing Bilateral Clareon TruPlus and Bilateral Clareon Monofocal Intraocular Lens Implantation (Spherical and Toric) in Cataract Subjects
NCT076932051 location